180 Life Sciences Corp.

Health Care
Biotechnology: Pharmaceutical Preparations
www.180lifesciences.com

Earnings Score

Market Cap $1.85M
PE 0
Debt $NaN
Cash $194.92K
EV $NaN
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$16.97M
EBIT	$10.51M
ROE	455%
ROA	100%
Equity	$3.73M
Growth Stability	-7K%
PE	0.11
PB	0.5
Price/Cash	0.11
Earnings CAGR	9%
Equity CAGR	12%
Earnings Stability	-0.1
Earnings Growth YoY	-32%

Equity CAGR 5Y	-8%
Equity CAGR 3Y	-21%
Market Cap	$1.85M
Assets	$10.47M
Cash	$194.92K
Shares Outstanding	845.84K
Earnings Score	6%
Working Capital	-5.16M
Current Ratio	0.19
Shares Growth 3y	15%
Equity Growth QoQ	-993%
Equity Growth YoY	-3K%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.

SEC Filings

Direct access to 180 Life Sciences Corp. (ATNF) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does 180 Life Sciences Corp. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of 180 Life Sciences Corp. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 9%

Stability -10%

loading chart...

180 Life Sciences Corp. Discounted Cash Flow

Fully customizable DCF calculator online for 180 Life Sciences Corp..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	09/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	05/2024	TTM
Net Margins	-	-	-	-	-	-	-	-	-	-
ROA	-	0%	1%	1%	-10%	-25%	-91%	-256%	-	100%
ROE	-	2%	21%	-66%	-40%	-52%	-341%	16K%	-	455%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	09/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	05/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	0.01	0.06	-	0.23	-	-	-
Growth Stability	-	-	-	-7K%	-	-	-	-	-	-7K%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-7K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	09/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	05/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	-18K%	741%	-3K%	-53%	69%	91%	-49%	-	-
Equity YoY growth	-	-	0%	671%	-21%	30%	-71%	-101%	-	-8%
FCF YoY growth	-	-	-	-	-	-	-	-	-	-